This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Results From Kadcyla® Phase III Trial, TH3RESA, Being Presented Today At The European Cancer Congress

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced the results from Roche’s TH3RESA Phase III trial being presented today at the European Cancer Congress (ECC) in Amsterdam (abstract #LBA15). The findings were accepted as late-breaking data and also included in the Congress’s official press program.

The TH3RESA study assessed Kadcyla (ado-trastuzumab emtansine) for the treatment of advanced HER2-positive breast cancer that had progressed despite prior treatment with at least two HER2-targeted medicines. At a minimum, patients must have received Herceptin® (trastuzumab), Tykerb® (lapatinib), and a taxane. The trial included approximately 600 patients who were randomized, on a two-to-one basis, to receive either Kadcyla or a treatment of their physician’s choice. Eighty percent of the patients treated with physician’s choice received a regimen containing Herceptin plus a second agent.

Kadcyla was found to significantly extend duration of progression-free survival (PFS) compared to treatment with physician’s choice (median 6.2 months vs. 3.3 months, respectively) and reduced the risk of disease progression or death by 47 percent (HR=0.528; p<0.0001). In the planned interim analysis, overall survival (OS) favored Kadcyla, but the data are not yet mature. PFS and OS are co-primary endpoints of the trial. No new safety signals were observed with Kadcyla.

Based on the earlier EMILIA Phase III trial, Kadcyla is approved for marketing in several countries, including the US, Japan, Switzerland, Canada, and Australia, with additional approvals expected. EMILIA assessed Kadcyla for the treatment of patients with HER2-positive metastatic breast cancer who had received prior treatment with Herceptin and a taxane chemotherapy. To be eligible for inclusion in the TH3RESA trial, patients would also need to have previously received treatment with Tykerb.

“The TH3RESA trial provides further support of improved progression-free survival with Kadcyla in patients with advanced HER2-positive breast cancer,” commented Dan Junius, President and CEO. “We are delighted that our technology is helping make such an important difference to patients.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs